BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18077168)

  • 1. Effectively nursing patients receiving aromatase inhibitor therapy.
    Wengström Y
    Breast; 2008 Jun; 17(3):227-38. PubMed ID: 18077168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C
    Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
    Dent SF; Gaspo R; Kissner M; Pritchard KI
    Breast Cancer Res Treat; 2011 Apr; 126(2):295-310. PubMed ID: 21249443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy for early breast cancer: the story so far.
    Gradishar WJ
    Cancer Invest; 2010 May; 28(4):433-42. PubMed ID: 20307199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Menopausal symptoms and adjuvant therapy-associated adverse events.
    Hadji P
    Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating trial data into patients benefits: making the right choice.
    Chlebowski RT
    Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
    Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
    Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.
    Cella D; Fallowfield LJ
    Breast Cancer Res Treat; 2008 Jan; 107(2):167-80. PubMed ID: 17876703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in adjuvant endocrine therapy for postmenopausal women.
    Lin NU; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the BIG results: the Breast International Group 1-98 trial analyses.
    Doughty JC
    Breast; 2008 Jan; 17 Suppl 1():S9-S14. PubMed ID: 18279765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
    Schwartzberg LS; Cobb P; Senecal F; Henry D; Kulig K; Walker MS; Houts AC; Stepanski EJ
    Breast; 2009 Apr; 18(2):78-83. PubMed ID: 19342237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Abdulhaq H; Geyer C
    Am J Clin Oncol; 2008 Dec; 31(6):595-605. PubMed ID: 19060594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
    Toi M; Yamashiro H; Tsuji W
    Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.
    Coleman RE; Bolten WW; Lansdown M; Dale S; Jackisch C; Merkel D; Maass N; Hadji P
    Cancer Treat Rev; 2008 May; 34(3):275-82. PubMed ID: 18082328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.